• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Astellas, PeptiDream Announce Protein Degrader Research Collaboration


Agreement to focus on two targets selected by pharma company.

Amyloid plaques forming between neurons. Beta-amyloid protein disrupting nerve cells function in a brain with Alzheimer's disease. Image Credit: Adobe Stock Images/nobeastsofierce

Image Credit: Adobe Stock Images/nobeastsofierce

Astellas and PeptiDream Inc. have announced a research partnership with the goal of discovering novel protein degraders for two targets selected by Astellas. With PeptiDream receiving an upfront payment of approximately $22 billion, Astellas will receive the option to select up to three more targets to be included in the collaboration. Upon reaching milestones of discovery, development, and commercial sales, PeptiDream will be eligible to receive an additional $146 billion.

“Targeted Protein Degradation is one of the Primary Focuses of Astellas,” said Adam Pearson, CEO, Astellas, in a company press release. “We hope this collaboration will bring synergies between the two companies' cutting-edge research and will ultimately lead to the expansion of Astellas’ portfolio and development of new therapeutics for patients with significant unmet medical needs.”

Reference: Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders. BusinessWire. July 25, 2023. Accessed July 25, 2023. https://www.businesswire.com/news/home/20230725980889/en/Astellas-and-PeptiDream-Enter-into-Research-Collaboration-and-License-Agreement-to-Discover-Novel-Targeted-Protein-Degraders

Recent Videos
Related Content